Pharming Group N.V. Files 6-K with March 13 Press Release
Ticker: PHAR · Form: 6-K · Filed: 2025-03-13T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, press-release, regulatory-update
TL;DR
Pharming Group N.V. dropped a 6-K on 3/13 with a press release - check it out.
AI Summary
Pharming Group N.V. filed a Form 6-K on March 13, 2025, furnishing a press release dated March 13, 2025, as Exhibit 99.1. The filing is for the month of March 2025 and indicates the company is a foreign private issuer filing under the 1934 Act. Pharming Group N.V. is incorporated in the Netherlands and its fiscal year ends on December 31.
Why It Matters
This filing provides an update from Pharming Group N.V. to the SEC, likely containing important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic updates, not usually indicative of immediate high risk.
Key Numbers
- 001-39822 — Commission File Number (Identifies the specific SEC filing record for Pharming Group N.V.)
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- March 13, 2025 (date) — Press Release Date
- 001-39822 (other) — Commission File Number
- 2333 CR Leiden (location) — Company Address
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release dated March 13, 2025, as Exhibit 99.1, to the U.S. Securities and Exchange Commission.
What is the exact date of the press release furnished with this filing?
The press release furnished with this filing is dated March 13, 2025.
What is the Commission File Number for Pharming Group N.V.?
The Commission File Number for Pharming Group N.V. is 001-39822.
Where are Pharming Group N.V.'s principal executive offices located?
Pharming Group N.V.'s principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Does Pharming Group N.V. file annual reports under Form 20-F or Form 40-F?
Pharming Group N.V. files annual reports under cover of Form 20-F.
From the Filing
0001828316-25-000012.txt : 20250313 0001828316-25-000012.hdr.sgml : 20250313 20250313061913 ACCESSION NUMBER: 0001828316-25-000012 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250313 FILED AS OF DATE: 20250313 DATE AS OF CHANGE: 20250313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 25733727 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2024q4pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated March 13, 2025. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports fourth quarter and full year 2024 financial results and provides business update SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: March 13, 2025 2 Pharming Group reports fourth quarter and full year 2024 financial results and provides business update • Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth • Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023 • RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023 • Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023 • Fourth quarter operating profit increased to US$6.7 million from US$1.1 million in the fourth quarter 2023 • Generated operating profit and positive net cash flows from operations for the second quarter in a row • Two ongoing Phase II clinical trials of leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, including common variable immunodeficiency (CVID) • Completed the acquisition of Abliva AB, adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company • Fabrice Chouraqui appointed as Chief Executive Officer and Executive Director at EGM held on March 4, 2025 • 2025 total revenu